Long-term benefits of weight-loss surgery in young people with severe obesity

Young people with severe obesity who underwent weight-loss surgery at age 19 or younger continued to see sustained weight loss and resolution of common obesity-related comorbidities 10 years later, according to results from a large clinical study funded by the National Institutes of Health (NIH).

Study participants with an average age of 17 underwent gastric bypass or sleeve gastrectomy weight-loss surgery. After 10 years, participants sustained an average of 20% reduction in body mass index (BMI), 55% reduction of type 2 diabetes, 57% reduction of hypertension, and 54% reduction of abnormal cholesterol. Both gastric bypass and sleeve gastrectomy had similar results.

The 55% reduction in type 2 diabetes was much higher than the rates observed in adults after weight-loss surgery (18% at seven years and 12.7% at 12 years) in a recently published NIH-funded study.

Type 2 diabetes tends to progress more rapidly when it occurs in young people, and these findings demonstrate the greater health benefits and durability of bariatric surgery in youth than would be expected in similarly treated adults.

The study, known as Teen Longitudinal Assessment of Bariatric Surgery (Teen LABS), was supported by NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through grants DK072493, DK072493, DK095710 and NIH's National Center for Research Resources and the National Center for Advancing Translational Sciences Clinical and Translational Science Awards Program grants TR000077 and TR000114.

Data related to these findings are available for request at the NIDDK Central Repository.

Voula Osganian, M.D., a pediatric clinical obesity program director at NIDDK is available to comment on this research.

Source:
Journal reference:

Ryder, J. R., et al. (2024) Ten-Year Outcomes after Bariatric Surgery in Adolescents. New England Journal of Medicine. doi.org/10.1056/nejmc2404054.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients